Inhibition of IL‐17–committed T cells in a murine psoriasis model by a vitamin D analogue

[1]  K. Tasanen,et al.  Clinical Efficiency of Topical Calcipotriol/Betamethasone Treatment in Psoriasis Relies on Suppression of the Inflammatory TNFα - IL-23 - IL-17 Axis. , 2017, Acta dermato-venereologica.

[2]  Y. Tokura,et al.  Topical application of a vitamin D3 analogue and corticosteroid to psoriasis plaques decreases skin infiltration of TH17 cells and their ex vivo expansion. , 2016, The Journal of allergy and clinical immunology.

[3]  Y. Tokura,et al.  Calcipotriol and betamethasone dipropionate exert additive inhibitory effects on the cytokine expression of inflammatory dendritic cell-Th17 cell axis in psoriasis. , 2016, Journal of dermatological science.

[4]  A. Nast,et al.  Methods Report: European S3‐Guidelines on the systemic treatment of psoriasis vulgaris – update 2015 – EDF in cooperation with EADV and IPC , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[5]  A. Bowcock,et al.  The immunogenetics of Psoriasis: A comprehensive review. , 2015, Journal of autoimmunity.

[6]  B. Becher,et al.  Dermal IL‐17‐producing γδ T cells establish long‐lived memory in the skin , 2015, European journal of immunology.

[7]  Elizabeth E Gray,et al.  Inflammation induces dermal Vγ4+ γδT17 memory-like cells that travel to distant skin and accelerate secondary IL-17–driven responses , 2015, Proceedings of the National Academy of Sciences.

[8]  J. Soung,et al.  The role of vitamin D in psoriasis: a review , 2015, International journal of dermatology.

[9]  A. Visekruna,et al.  Transcription factor c-Rel plays a crucial role in driving anti-CD40-mediated innate colitis , 2014, Mucosal Immunology.

[10]  F. Bernard,et al.  Inhibition of Keratinocyte Differentiation by the Synergistic Effect of IL-17A, IL-22, IL-1α, TNFα and Oncostatin M , 2014, PloS one.

[11]  M. Kubo,et al.  Basophils regulate the recruitment of eosinophils in a murine model of irritant contact dermatitis. , 2014, The Journal of allergy and clinical immunology.

[12]  B. Malissen,et al.  IL-23 from Langerhans cells is required for the development of imiquimod-induced psoriasis-like dermatitis by induction of IL-17A-producing γδ T cells. , 2014, The Journal of investigative dermatology.

[13]  Huang-Ge Zhang,et al.  Differential Developmental Requirement and Peripheral Regulation for Dermal Vγ4 and Vγ6T17 Cells in Health and Inflammation , 2014, Nature Communications.

[14]  F. Qiu,et al.  γδT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. , 2014, Immunity.

[15]  U. V. von Andrian,et al.  Nociceptive Sensory Neurons Drive Interleukin-23 Mediated Psoriasiform Skin Inflammation , 2014, Nature.

[16]  Mayte Suárez-Fariñas,et al.  Immunology of psoriasis. , 2014, Annual review of immunology.

[17]  W. Dou,et al.  A comparison of the effects of topical treatment of calcipotriol, camptothecin, clobetasol and tazarotene on an imiquimod-induced psoriasis-like mouse model , 2014, Immunopharmacology and immunotoxicology.

[18]  G. Ogg,et al.  A role for IL-25 and IL-33–driven type-2 innate lymphoid cells in atopic dermatitis , 2013, The Journal of experimental medicine.

[19]  B. Becher,et al.  Langerinneg conventional dendritic cells produce IL-23 to drive psoriatic plaque formation in mice , 2013, Proceedings of the National Academy of Sciences.

[20]  David A. Martin,et al.  The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. , 2013, Trends in immunology.

[21]  Elizabeth E Gray,et al.  IL-17-committed Vγ4+ γδ T cell deficiency in a spontaneous Sox13 mutant CD45.1 congenic mouse substrain protects from dermatitis , 2013, Nature Immunology.

[22]  M. Campbell,et al.  Vitamin D receptor signaling mechanisms: Integrated actions of a well-defined transcription factor , 2013, Steroids.

[23]  M. Hepworth,et al.  TSLP Elicits IL-33–Independent Innate Lymphoid Cell Responses to Promote Skin Inflammation , 2013, Science Translational Medicine.

[24]  K. Okkenhaug,et al.  Blockade of Phosphatidylinositol 3-Kinase (PI3K)δ or PI3Kγ Reduces IL-17 and Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis , 2012, The Journal of Immunology.

[25]  S. Werner,et al.  Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. , 2012, The Journal of clinical investigation.

[26]  G. Girolomoni,et al.  Psoriasis: rationale for targeting interleukin‐17 , 2012, The British journal of dermatology.

[27]  C. Hawrylowicz,et al.  The role of 1α,25‐dihydroxyvitamin D3 and cytokines in the promotion of distinct Foxp3+and IL‐10+ CD4+ T cells , 2012, European journal of immunology.

[28]  S. Imafuku,et al.  Topical vitamin D3 analogues induce thymic stromal lymphopoietin and cathelicidin in psoriatic skin lesions , 2012, The British journal of dermatology.

[29]  Jun Yan,et al.  New insights of T cells in the pathogenesis of psoriasis , 2012, Cellular and Molecular Immunology.

[30]  B. Becher,et al.  Rorγt+ innate lymphocytes and γδ T cells initiate psoriasiform plaque formation in mice. , 2012, The Journal of clinical investigation.

[31]  T. Ruzicka,et al.  Vitamin D analog calcipotriol suppresses the Th17 cytokine-induced proinflammatory S100 "alarmins" psoriasin (S100A7) and koebnerisin (S100A15) in psoriasis. , 2012, The Journal of investigative dermatology.

[32]  V. Jala,et al.  Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation. , 2011, Immunity.

[33]  J. Renauld,et al.  IL-22 Is Required for Imiquimod-Induced Psoriasiform Skin Inflammation in Mice , 2011, The Journal of Immunology.

[34]  A. Hayday,et al.  Identification of a Novel Proinflammatory Human Skin-Homing Vγ9Vδ2 T Cell Subset with a Potential Role in Psoriasis , 2011, The Journal of Immunology.

[35]  A. Gottlieb,et al.  Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. , 2011, Journal of the American Academy of Dermatology.

[36]  J. Ashkenas,et al.  Canadian Guidelines for the Management of Plaque Psoriasis: Overview , 2011, Journal of cutaneous medicine and surgery.

[37]  J. Krueger,et al.  Contrasting pathogenesis of atopic dermatitis and psoriasis--part II: immune cell subsets and therapeutic concepts. , 2011, The Journal of allergy and clinical immunology.

[38]  K. Schäkel,et al.  Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1 T-cell responses. , 2011, The Journal of allergy and clinical immunology.

[39]  W. Ouyang.  Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease. , 2010, Cytokine & growth factor reviews.

[40]  A. Gottlieb,et al.  Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis. , 2010, Journal of the American Academy of Dermatology.

[41]  K. Mills,et al.  Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. , 2009, Immunity.

[42]  D. Fuchs,et al.  Phenotypic and functional markers for 1α,25‐dihydroxyvitamin D3‐modified regulatory dendritic cells , 2009, Clinical and experimental immunology.

[43]  C. Conrad,et al.  Interplay between keratinocytes and immune cells--recent insights into psoriasis pathogenesis. , 2009, The international journal of biochemistry & cell biology.

[44]  L. Boon,et al.  Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis1 , 2009, The Journal of Immunology.

[45]  T. Ruzicka,et al.  IL-17A Enhances Vitamin D3-Induced Expression of Cathelicidin Antimicrobial Peptide in Human Keratinocytes1 , 2008, The Journal of Immunology.

[46]  M. Haniffa,et al.  Differential regulation of naïve and memory CD4+ T cells by alternatively activated dendritic cells , 2008, Journal of leukocyte biology.

[47]  L. Fouser,et al.  IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. , 2008, The Journal of clinical investigation.

[48]  Kathleen M. Smith,et al.  Development, cytokine profile and function of human interleukin 17–producing helper T cells , 2007, Nature Immunology.

[49]  F. Sallusto,et al.  Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17–producing human T helper cells , 2007, Nature Immunology.

[50]  James G. Krueger,et al.  Pathogenesis and therapy of psoriasis , 2007, Nature.

[51]  L. Fouser,et al.  Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides , 2006, The Journal of experimental medicine.

[52]  P. Chambon,et al.  Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[53]  P. Perrin,et al.  Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. , 2005, Immunity.

[54]  T. Mcclanahan,et al.  IL-23 drives a pathogenic T cell population that induces autoimmune inflammation , 2005, The Journal of experimental medicine.

[55]  L. Adorini,et al.  Suppressive Effect of 1α,25-Dihydroxyvitamin D3 on Type I IFN-Mediated Monocyte Differentiation into Dendritic Cells: Impairment of Functional Activities and Chemotaxis1 , 2005, The Journal of Immunology.

[56]  C. Mathieu,et al.  1alpha,25-dihydroxyvitamin D3 or analogue treated dendritic cells modulate human autoreactive T cells via the selective induction of apoptosis. , 2004, Journal of autoimmunity.

[57]  M. Uskoković,et al.  Dendritic cells as key targets for immunomodulation by Vitamin D receptor ligands , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[58]  N. Romani,et al.  Langerhans cells – dendritic cells of the epidermis , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[59]  M. Uskoković,et al.  Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases , 2003 .

[60]  M. Uskoković,et al.  A 1α,25-Dihydroxyvitamin D3 Analog Enhances Regulatory T-Cells and Arrests Autoimmune Diabetes in NOD Mice , 2002 .

[61]  M. Cork,et al.  Topical preparations for the treatment of psoriasis: a systematic review , 2002, The British journal of dermatology.

[62]  H. Drexhage,et al.  1-alpha,25-Dihydroxyvitamin D3 (1,25(OH)(2)D(3)) hampers the maturation of fully active immature dendritic cells from monocytes. , 2001, European journal of endocrinology.

[63]  L. Adorini,et al.  Regulatory T Cells Induced by 1α,25-Dihydroxyvitamin D3 and Mycophenolate Mofetil Treatment Mediate Transplantation Tolerance1 , 2001, The Journal of Immunology.

[64]  R. Kumar,et al.  Dendritic cell modulation by 1α,25 dihydroxyvitamin D3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[65]  C. Caux,et al.  Up-Regulation of Macrophage Inflammatory Protein-3α/CCL20 and CC Chemokine Receptor 6 in Psoriasis1 , 2000, The Journal of Immunology.

[66]  O. Majdic,et al.  1,25-Dihydroxyvitamin D(3) inhibits dendritic cell differentiation and maturation in vitro. , 2000, Experimental hematology.

[67]  P. Allavena,et al.  Vitamin D3 Affects Differentiation, Maturation, and Function of Human Monocyte-Derived Dendritic Cells1 , 2000, The Journal of Immunology.

[68]  R. Kumar,et al.  Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. , 2000, Biochemical and biophysical research communications.

[69]  M. Cork,et al.  Topical preparations for the treatment of psoriasis: a systematic review , 2000, The British journal of dermatology.

[70]  L. Adorini,et al.  1α,25-Dihydroxyvitamin D3 Inhibits Differentiation, Maturation, Activation, and Survival of Dendritic Cells Leading to Impaired Alloreactive T Cell Activation , 2000, The Journal of Immunology.

[71]  Harris,et al.  Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo‐controlled, double‐blind, dose‐finding study with active comparator , 1999, The British journal of dermatology.

[72]  T. Luger,et al.  Tacalcitol ointment in the treatment of psoriasis vulgaris:a multicentre, placebo‐controlled, double‐blind study on efficacy and safety , 1996, The British journal of dermatology.

[73]  W. Cunliffe,et al.  Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. , 1992, Journal of the American Academy of Dermatology.

[74]  M. Haussler,et al.  Expression of 1,25-dihydroxyvitamin D3 receptors in normal and psoriatic skin. , 1991, The Journal of investigative dermatology.

[75]  D. Hoop,et al.  Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris , 1991, The Lancet.

[76]  R. Steinman,et al.  Migration and maturation of Langerhans cells in skin transplants and explants , 1990, The Journal of experimental medicine.

[77]  K. Kragballe,et al.  Improvement of psoriasis by a topical vitamin D3 analogue (MC 903) in a double‐blind study , 1988, The British journal of dermatology.

[78]  D. Katz,et al.  Dendritic cells from human tissues express receptors for the immunoregulatory vitamin D3 metabolite, dihydroxycholecalciferol. , 1987, Immunology.

[79]  S. Manolagas,et al.  1,25-dihydroxyvitamin D3 receptors in human leukocytes. , 1983, Science.

[80]  K. Kragballe,et al.  Calcipotriol (MC 903), a novel vitamin D3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes , 2004, Archives of Dermatological Research.

[81]  M. Cippitelli,et al.  Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. , 1998, The Journal of clinical investigation.

[82]  J. Quell,et al.  Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group. , 1995, Journal of the American Academy of Dermatology.